Evidence map›Paper›PMID 39959567›Full record

ArticleJournal of skin cancer2025

Survival Outcomes of a Large Cohort of Acral Melanoma Patients Treated at a South African Referral Hospital.

Bianca Tod, Tonya Esterhuizen, Willem Visser, Maritha Kotze, Anne Bowcock, Johann Schneider, Henriette Burger

Abstract read
In one paragraph

Article in Journal of skin cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bianca TodDivision of Dermatology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-8204-8478
Tonya EsterhuizenDivision of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-8703-1664
Willem VisserDivision of Dermatology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-2701-4632
Maritha KotzeDivision of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Tygerberg Academic Hospital, Stellenbosch University and National Health Laboratory Service, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-6050-2876
Anne BowcockDepartments of Dermatology, Oncological Sciences and Genetics & Genome Science, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0001-8691-9090
Johann SchneiderDivision of Anatomical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Tygerberg Academic Hospital, Stellenbosch University and National Health Laboratory Service, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-5187-6756
Henriette BurgerDivision of Radiation Oncology, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-3941-568X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acral melanoma (AM) is the most common type of melanoma arising in people with skin of color. AM is often diagnosed late and associated with poor outcomes. Melanoma outcomes are also impacted by socioeconomic status. Although uncommon, AM is a public health concern in South Africa because of its epidemiology and association with health access issues, which predispose to late diagnosis. South African patients are managed based on staging systems and treatment guidelines developed for other populations. This cohort study aimed to determine the survival outcomes in a cohort of South African AM patients and how these were associated with demographic, clinical, pathological, and management data. The study included patients diagnosed at a referral hospital between 1 January 2010 and 31 December 2021. Analysis occurred in 2022 and 2023. The main outcomes of interest were survival time in months (overall and progression-free, OS and PFS). Survival outcomes were analyzed using Kaplan-Meier survival curves. Survival probabilities were compared between subgroups using log-rank tests. Univariate and multivariable analyses were performed using the Cox proportional hazards models to assess factors associated with survival. Ninety-one patients were included in the analysis. After a median follow-up of 28 months (range: 0-151 months), 48 patients (52.7%) had died. The 3- and 5-year survival rates for the entire cohort were 64.8% and 56.0% respectively. Notably, the OS and PFS were not affected by the population group (

Identifiers

PMID39959567
PMCPMC11824689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.